Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NR90
UPID:
DAZ3_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NR90; Q2KHN7
Background:
Deleted in azoospermia protein 3, encoded by the gene with accession number Q9NR90, is pivotal in spermatogenesis. It functions as an RNA-binding protein, crucially regulating the translation of mRNAs by binding to their 3'-UTR. This protein's role is integral in the production and maturation of sperm.
Therapeutic significance:
Spermatogenic failure Y-linked 2, a condition marked by reduced or absent sperm leading to male infertility, is associated with this protein. Variants affecting this gene, particularly AZFc deletions in the Yq11.23 region, are a significant genetic cause of infertility. Understanding the role of Deleted in azoospermia protein 3 could open doors to potential therapeutic strategies.